Drugs Made in America Acquisition Corp. II (NASDAQ:DMAAU) announced the pricing of its $500 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “DMIIU”, Thursday, September 25, 2025.

The new SPAC intends to target in the pharmaceutical industry that can serve as a platform company for further M&A.

Drugs Made in America II’s sponsor team is led by Chief Executive Officer and Executive Chair Lynn Stockwell, and Chief Financial Officer Glenn Worman. Catherine Do, G. Sridhar Prasad and Myron W. Shulgan will serve on its Board of Directors.

Total SPAC deal count for 2025 year-to-date is now 93. This offering is expected to close on Friday, September 26, 2025.

Cantor Fitzgerald & Co. is acting as the sole book-running manager in the offering. Loeb & Loeb LLP is serving as Issuer’s Counsel with Ellenoff Grossman & Schole LLP serving as Underwriter’s Counsel. MaloneBailey LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.